Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CD-NP · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Open-label regimen of doses 1 and 2 of CDNP |
| B | EXPERIMENTAL | Open-label regimen of doses 2 and 3 of CDNP |
| C | EXPERIMENTAL | Open-label regimen of doses 3 and 4 of CDNP |
| Name | Type | Description |
|---|---|---|
| CD-NP (Chimeric natriuretic peptide) | DRUG | Infusion of CDNP at two of four doses |
Key Inclusion Criteria: * Hospitalization for AHF * In need of hemodynamic monitoring Key Exclusion Criteria: * Administration of intravenous radiographic contrast agent within 7 days prior to screening or planned IV contrast media administration in the 4 days after screening or acute contrast-in...
CD-NP is an investigational small molecule being developed for the treatment of Acute Decompensated Heart Failure. It is a chimeric natriuretic peptide studied for its hemodynamic effects in patients with stabilized acute heart failure. The drug is currently in clinical development and has not been approved by regulatory authorities.
CD-NP is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker YCBD. The drug is in Phase 2 clinical development for Acute Decompensated Heart Failure, a cardiovascular condition.
CD-NP is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. A Phase 2 clinical trial has been completed to assess its hemodynamic effects, safety, and tolerability in patients with stabilized acute heart failure.
CD-NP has one completed clinical trial registered under NCT00699712. This Phase 2 study assessed hemodynamic effects, safety, and tolerability of CD-NP in patients with stabilized acute heart failure. The trial enrolled 30 participants in Russia and included patients aged 18 years and older.
Yes, CD-NP is also known as chimeric natriuretic peptide. The clinical trial NCT00699712 refers to the drug as 'Chimeric Natriuretic Peptide (CD-NP)' in its title. This alternative name may be used in scientific literature and clinical trial registries.